Formulary Decisions

Indication

For the treatment of obesity prioritised for use in those with a BMI of ≥38kg/m2 (≥35kg/m2 for members of minority ethnic groups known to be at equivalent risk of the consequences of obesity at a lower BMI than the white population) in the presence of at least one weight-related comorbidity. For ...

For the treatment of obesity prioritised for use in those with a BMI of ≥38kg/m2 (≥35kg/m2 for members of minority ethnic groups known to be at equivalent risk of the consequences of obesity at a lower BMI than the white population) in the presence of at least one weight-related comorbidity. For more information, refer to: Consensus statement: national criteria for the prioritisation of glucagon like peptide-1 receptor agonists (GLP-1 RAs) and GLP-1 RA/glucose-dependent insulinotropic polypeptide receptor agonists (GIP RAs) for the treatment of obesity in NHS Scotland, NHS Scotland Publications.